Claim 20% Off Global Market Reports With Code ONLINE20 – Insights on Tariff Effects, Global Trade, and Industry Disruptors

How Will The Guillain-Barre Syndrome Drugs Market Valuation Change Between Now And 2029?

In the past few years, the market size of drugs for Guillain-Barre syndrome has seen significant growth. The market is projected to expand from $1.17 billion in 2024 to $1.25 billion in 2025, demonstrating a compound annual growth rate (CAGR) of 7.2%. The acceleration during the historical period can be traced back to advancements in research and development, governmental initiatives and regulatory support, heightened attention towards neurology and autoimmune diseases, a rising emphasis on minimising healthcare expenses, and swelling requirement for hospital and clinic services.

There is an expectation of prominent growth for the Guillain-Barre Syndrome drugs market in the coming years, with a projected growth to a worth of “$1.64 billion in 2029 at an annual growth of 7.0% (Compound Annual Growth Rate or CAGR). This promising upswing during the forecast period is largely courtesy of factors such as an increased incidence of Guillain-Barre Syndrome (GBS), improved diagnosis and recognition rates, a rise in the elderly population, the growing influence of hospital and retail pharmacies, and a surged demand for both oral and parenteral drugs. Essential shifts foreseen during this period involve the creation of innovative therapies, progress in diagnostic devices, cooperation between pharmaceutical enterprises and research bodies, enhancements in gene therapy, and advancements in intravenous immunoglobulin therapy.

Get A Free Sample Of The Report:

https://www.thebusinessresearchcompany.com/sample.aspx?id=15581&type=smp

What Drivers Are Accelerating Expansion Of The Guillain-Barre Syndrome Drugs Market?

The surge in interest for personalized healthcare is predicted to stimulate the expansion of the Guillain-Barre syndrome drugs market in forthcoming years. The concept of personalized medicine revolves around the adjustment of medical treatments to fit individual traits like genetic makeup or lifestyle habits, which aids in enhancing efficacy and lowering negative effects. This uptick in interest for bespoke healthcare comes with the promise of improved treatment methods, advances in genomics, escalated complexity of diseases, and regulatory backing. In the case of Guillain-Barre syndrome (GBS), personalized medicine aspires to curate treatments based on distinct patient profiles, so as to heighten therapeutic results and decrease harmful effects. As an illustration, the Personalized Medicine Coalition, a non-profit organization based in the US, stated in February 2024 that compared to only six in 2022, the FDA (Food and Drug Administration), a federal agency also based in the US, sanctioned 16 new personalized therapies for patients suffering from rare illnesses in 2023. Therefore, this escalated demand for personalized healthcare is propelling the expansion of the Guillain-Barre syndrome drugs market.

What Are The Key Segment Trends Observed In The Guillain-Barre Syndrome Drugs Market?

The guillain-barre syndrome drugs market covered in this report is segmented –

1) By Drug Class: Immunoglobulins (IVIG), Corticosteroids, Plasma Exchange

2) By Treatment Type: First-Line Treatment, Adjunctive Or Supportive Treatment

3) By Application: Clinic, Hospital, Other Applications

Subsegments:

1) By Immunoglobulins (Ivig): Intravenous Immunoglobulin (Ivig) Therapy, Human Normal Immunoglobulin (Hnig), Hyperimmune Immunoglobulin Products, Ivig Formulations For Gbs Treatment, Monoclonal Antibodies As Part Of Ivig Treatment

2) By Corticosteroids: Methylprednisolone, Prednisolone, Dexamethasone, Hydrocortisone, Betamethasone, Oral Corticosteroid Formulations

3) By Plasma Exchange: Therapeutic Plasma Exchange (Tpe), Plasmapheresis Equipment For Gbs Treatment, Centrifugal Plasma Exchange, Immunoadsorption Plasma Exchange, Autologous Plasma Exchange (Ape)

Which Disruptive Trends Are Driving Change Across The Guillain-Barre Syndrome Drugs Market?

To maintain their market positions in the guillain-barre syndrome drugs sector, leading firms are focusing on the creation of unique products like humanized monoclonal antibodies. This type of antibody, which is synthesized in the lab by merging a human antibody with a small segment of a mouse or rat monoclonal antibody, is being investigated for its therapeutic potential due to its ability to specifically target key components of the immune system that play a role in the progression of GBS (Guillan-Barre syndrome). For example, Annexon Inc., an American clinical-stage biopharmaceutical firm, announced in October 2023 that ANX005, a humanized monoclonal antibody that impedes C1q to prevent complement-mediated inflammation and early neuronal damage in GBS, had been granted the status of an orphan drug by both the European Medicines Agency (EMA) and the U.S. Food and Drug Administration (FDA). Annexon has met its target enrollment for a Phase 3 trial of ANX005 in GBS, with preliminary data estimated to be available in the first half of 2024. The objective of ANX005 is to decrease inflammation and nerve damage by specifically blocking C1q activity in the nervous system, which would lead to a quick cessation of autoimmune damage and recovery of muscle strength in GBS patients.

Which Firms Are Driving Innovation Within The Guillain-Barre Syndrome Drugs Market?

Major companies operating in the guillain-barre syndrome drugs market are F. Hoffmann-La Roche Ltd., Merck & Co. Inc., AbbVie Inc., Novartis AG, Takeda Pharmaceutical Company Limited, Biogen Inc., Chugai Pharmaceutical Co. Ltd., Grifols SA, Octapharma AG, Cadila Healthcare Limited, Argenx SE, Alnylam Pharmaceuticals Inc., Biotest AG, CSL Behring LLC, Kedrion Biopharma Inc., Cellenkos Inc., Annexon Inc., Hansa Medical AB, Akari Therapeutics Plc, Alexion Pharmaceuticals Inc., Vitality Biopharma Inc., CuraVac Inc., Regenesance BV, Cresence AS, Shire Plc

Access The Complete Report Here:

https://www.thebusinessresearchcompany.com/report/guillain-barre-syndrome-drugs-global-market-report

What Regional Factors Are Accelerating Growth In The Guillain-Barre Syndrome Drugs Market?

North America was the largest region in the guillain-barre syndrome drugs market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the guillain-barre syndrome drugs market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Customize Your Report Here:

https://www.thebusinessresearchcompany.com/customise?id=15581&type=smp

About The Business Research Company:

With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795

Asia +44 7882 955267 & +91 8897263534

Europe +44 7882 955267

Email us at info@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model